Next Article in Journal
Regulation of Photochemical Energy Transfer Accompanied by Structural Changes in Thylakoid Membranes of Heat-Stressed Wheat
Next Article in Special Issue
Crosstalk between Edc4 and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in mRNA Decapping
Previous Article in Journal
Effect of Hydrogen Peroxide on the Biosynthesis of Heme and Proteins: Potential Implications for the Partitioning of Glu-tRNAGlu between These Pathways
Previous Article in Special Issue
Comparative Proteomic Analysis of Labellum and Inner Lateral Petals in Cymbidium ensifolium Flowers
Open AccessReview

Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

1
Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark
2
Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany
3
Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C 8000, Denmark
4
Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Nørrebrogade 44, Aarhus C 8000, Denmark
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2014, 15(12), 23024-23041; https://doi.org/10.3390/ijms151223024
Received: 26 October 2014 / Revised: 5 December 2014 / Accepted: 6 December 2014 / Published: 11 December 2014
(This article belongs to the Collection Advances in Proteomic Research)
Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate. View Full-Text
Keywords: breast cancer; anti-angiogenic therapy; biomarkers; vascular endothelial growth factor breast cancer; anti-angiogenic therapy; biomarkers; vascular endothelial growth factor
Show Figures

Figure 1

MDPI and ACS Style

Kristensen, T.B.; Knutsson, M.L.T.; Wehland, M.; Laursen, B.E.; Grimm, D.; Warnke, E.; Magnusson, N.E. Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer. Int. J. Mol. Sci. 2014, 15, 23024-23041. https://doi.org/10.3390/ijms151223024

AMA Style

Kristensen TB, Knutsson MLT, Wehland M, Laursen BE, Grimm D, Warnke E, Magnusson NE. Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer. International Journal of Molecular Sciences. 2014; 15(12):23024-23041. https://doi.org/10.3390/ijms151223024

Chicago/Turabian Style

Kristensen, Tina B.; Knutsson, Malin L.T.; Wehland, Markus; Laursen, Britt E.; Grimm, Daniela; Warnke, Elisabeth; Magnusson, Nils E. 2014. "Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer" Int. J. Mol. Sci. 15, no. 12: 23024-23041. https://doi.org/10.3390/ijms151223024

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop